

Development of a novel small-molecule anti-obesity drug based on inhibition of ****

JW Pharmaceutical



| METABOLIC | Candidate |
|--------------------------|---|
| Product Type | Small molecule |
| Indication | Obesity |
| Target | **** |
| MoA(Mechanism of Action) | Anti-obesity & anti-inflammatory effect through **** inhibition |
| Competitiveness | Semaglutide (GLP-1 RA) |
| Development Stage | Candidate |
| Route of Administration | Oral |

Any unauthorized distribution or reproduction of this material is strictly prohibited.